CD274 and alveolar soft part sarcoma: A specific histological subtype, alveolar soft part sarcoma (ASPS), displays higher response rates and extended PFS,16, 17, 20, 21, 22 leading to a recent Food and Drug Administration approval of atezolizumab, an anti–programmed death‐ligand 1 (PD‐L1) antibody.